CN111032690B - 靶向骨的抗体 - Google Patents

靶向骨的抗体 Download PDF

Info

Publication number
CN111032690B
CN111032690B CN201880007783.2A CN201880007783A CN111032690B CN 111032690 B CN111032690 B CN 111032690B CN 201880007783 A CN201880007783 A CN 201880007783A CN 111032690 B CN111032690 B CN 111032690B
Authority
CN
China
Prior art keywords
ser
val
antibody
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880007783.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN111032690A (zh
Inventor
H·邱
S·帕克
J·斯特凡诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CN202410319667.1A priority Critical patent/CN118121696A/zh
Publication of CN111032690A publication Critical patent/CN111032690A/zh
Application granted granted Critical
Publication of CN111032690B publication Critical patent/CN111032690B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880007783.2A 2017-01-20 2018-01-19 靶向骨的抗体 Active CN111032690B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410319667.1A CN118121696A (zh) 2017-01-20 2018-01-19 靶向骨的抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
US62/448,763 2017-01-20
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410319667.1A Division CN118121696A (zh) 2017-01-20 2018-01-19 靶向骨的抗体

Publications (2)

Publication Number Publication Date
CN111032690A CN111032690A (zh) 2020-04-17
CN111032690B true CN111032690B (zh) 2024-03-26

Family

ID=61581744

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880007783.2A Active CN111032690B (zh) 2017-01-20 2018-01-19 靶向骨的抗体
CN202410319667.1A Pending CN118121696A (zh) 2017-01-20 2018-01-19 靶向骨的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410319667.1A Pending CN118121696A (zh) 2017-01-20 2018-01-19 靶向骨的抗体

Country Status (17)

Country Link
US (3) US10844115B2 (enExample)
EP (1) EP3571226A2 (enExample)
JP (3) JP7227138B2 (enExample)
KR (3) KR102613463B1 (enExample)
CN (2) CN111032690B (enExample)
AR (1) AR110755A1 (enExample)
AU (1) AU2018210270A1 (enExample)
BR (1) BR112019013986A2 (enExample)
CA (1) CA3050884A1 (enExample)
IL (2) IL268114B2 (enExample)
MX (2) MX2019008549A (enExample)
MY (2) MY207919A (enExample)
SG (1) SG11201906663VA (enExample)
TW (3) TWI832600B (enExample)
UY (1) UY37576A (enExample)
WO (1) WO2018136698A2 (enExample)
ZA (1) ZA201907673B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033614A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. Tgf-.beta. antagonist conjugates
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US20210155708A1 (en) * 2018-07-10 2021-05-27 Sanofi Combination therapies against cancer targeting cd38 and tgf-beta
EP3884066A2 (en) * 2018-11-19 2021-09-29 Biocartis NV Enhanced detection of low-copy-number nucleic acids in an integrated workflow
AU2022269615A1 (en) 2021-05-07 2023-12-21 Baylor College Of Medicine Treatment of moderate-to-severe osteogenesis imperfecta
CA3226401A1 (en) * 2021-07-20 2023-01-26 William Marsh Rice University Engineered compositions for bone-targeted therapy
CA3237245A1 (en) * 2021-11-01 2023-05-04 Genzyme Corporation Treatment of osteogenesis imperfecta
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
WO2015140150A1 (en) * 2014-03-17 2015-09-24 Piotr Jachimczak Combination for use in a method of treating cancer
CN105229028A (zh) * 2013-03-20 2016-01-06 建新公司 用于治疗成骨不全的方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US6455495B1 (en) 1997-02-14 2002-09-24 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
BR0317896A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Complexos de cristais de proteìna e polìmeros iÈnicos
WO2004098637A1 (en) 2003-04-30 2004-11-18 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
HUE055861T2 (hu) 2004-04-21 2021-12-28 Alexion Pharma Inc Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez
PT3520815T (pt) 2005-02-08 2022-02-02 Genzyme Corp Anticorpos contra tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
WO2007076391A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2008145142A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
EP3141561B1 (en) 2009-04-24 2018-09-12 Vanderbilt University Anti-tgf-beta induction of bone growth
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
CN116063522A (zh) 2011-06-13 2023-05-05 美国全心医药生技股份有限公司 抗psgl-1抗体及其用途
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2855527B1 (en) 2012-05-31 2018-08-01 Innate Pharma Tlr3 binding agents
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2908913B1 (en) 2012-10-17 2018-10-03 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
KR102630750B1 (ko) 2013-12-17 2024-01-30 제넨테크, 인크. Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
JP6901400B2 (ja) 2015-04-03 2021-07-14 ゾーマ テクノロジー リミテッド ＴＧＦ−β及びＰＤ−１の阻害物質を使用する癌の治療法
NZ735820A (en) 2015-04-17 2025-02-28 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
EP3344660B1 (en) * 2015-08-31 2025-03-05 National Research Council of Canada Tgf-beta-receptor ectodomain fusion molecules and uses thereof
CA3033614A1 (en) 2016-08-11 2018-02-15 Precithera, Inc. Tgf-.beta. antagonist conjugates
AR110755A1 (es) 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
CN105229028A (zh) * 2013-03-20 2016-01-06 建新公司 用于治疗成骨不全的方法
WO2015140150A1 (en) * 2014-03-17 2015-09-24 Piotr Jachimczak Combination for use in a method of treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The S228P mutation prevents in vivo and in vitro IgG4 Fab-arm exchange as demonstrated using a combination of novel quantitative immunoassays and physiological matrix preparation;Silva JP等;《J Biol Chem》;摘要，第5462页左栏第1段 *

Also Published As

Publication number Publication date
KR20190105236A (ko) 2019-09-16
IL317592A (en) 2025-02-01
MY207919A (en) 2025-03-27
CN111032690A (zh) 2020-04-17
ZA201907673B (en) 2021-05-26
WO2018136698A2 (en) 2018-07-26
MX2019008549A (es) 2019-09-11
KR20250012197A (ko) 2025-01-23
MX2022008073A (es) 2022-07-27
TWI832600B (zh) 2024-02-11
KR102613463B1 (ko) 2023-12-15
JP7597836B2 (ja) 2024-12-10
KR102755284B1 (ko) 2025-01-22
AU2018210270A1 (en) 2019-09-05
TWI788321B (zh) 2023-01-01
TW202421659A (zh) 2024-06-01
MY194819A (en) 2022-12-17
CA3050884A1 (en) 2018-07-26
WO2018136698A3 (en) 2018-08-30
EP3571226A2 (en) 2019-11-27
SG11201906663VA (en) 2019-08-27
IL268114B2 (en) 2025-05-01
IL268114B1 (en) 2025-01-01
US20210163584A1 (en) 2021-06-03
IL268114A (en) 2019-09-26
TW201839013A (zh) 2018-11-01
US20180208650A1 (en) 2018-07-26
JP2023058590A (ja) 2023-04-25
AR110755A1 (es) 2019-05-02
US12098194B2 (en) 2024-09-24
TW202330597A (zh) 2023-08-01
KR20230172039A (ko) 2023-12-21
US20250074975A1 (en) 2025-03-06
JP2020505919A (ja) 2020-02-27
BR112019013986A2 (pt) 2020-03-03
UY37576A (es) 2018-10-31
CN118121696A (zh) 2024-06-04
RU2019126026A (ru) 2021-02-20
US10844115B2 (en) 2020-11-24
JP7227138B2 (ja) 2023-02-21
RU2019126026A3 (enExample) 2021-11-09
JP2025028981A (ja) 2025-03-05

Similar Documents

Publication Publication Date Title
CN111032690B (zh) 靶向骨的抗体
KR20220110224A (ko) Bcma에 결합하는 항체 및 이의 용도
CN109476763A (zh) 双特异性蛋白质及其制备方法
KR102815628B1 (ko) 인간화 항-il17a 항체 및 이의 용도
CN108659112B (zh) 一种非对称双特异性抗体
CN115087673A (zh) 结合il4r的抗体及其用途
KR20240019218A (ko) T 세포 관여자 분자 및 이의 용도
AU2020316495A1 (en) Humanized anti-VEGF Fab antibody fragment and use thereof
KR20220071177A (ko) 인간화 항-vegf 단클론 항체
CN116925222A (zh) 抗pvrig抗体、其药物组合物及用途
CN104558194B (zh) 一类抗CD20-Flex双功能融合蛋白、其制备方法及用途
RU2801206C2 (ru) Антитела, нацеливающиеся на костную ткань
KR20210141794A (ko) 항포도플라닌 항체
JP7510209B2 (ja) ヘルパーＴ細胞ＴＧＦ－βシグナルを特異的に中和する二重特異性抗体、その薬物組成物およびその使用
KR20240019295A (ko) 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
RU2802960C2 (ru) Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ
HK1147107B (en) Improved antibody molecules
HK1147107A1 (en) Improved antibody molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment